“Who could have predicted the way it would go?” said Sophie McGrath, a partner at legal firm Goodwin’s technology and life sciences groups. In spring 2020 when COVID-19 reached Europe and the US, transactional lawyers were justifiably nervous about closing ongoing deals.
The nerves subsided somewhat when it was realized that “health care” had in fact rapidly become the center of global attention, the pandemic shining a spotlight on life sciences in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?